<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CONVENIA- cefovecin sodium injection, powder, lyophilized, for solution </strong><br>Zoetis Inc.<br></p></div>
<h1>convenia<span class="Sup">®</span><br> (cefovecin sodium)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">Antimicrobial for Subcutaneous Injection in Dogs and Cats Only</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION:</span> Cefovecin sodium is a semi-synthetic broad-spectrum antibacterial agent from the cephalosporin class of chemotherapeutic agents. Cefovecin is the non-proprietary designation for (6<span class="Italics">R</span>,7<span class="Italics">R</span>)-7-[[(2<span class="Italics">Z</span>)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[(2<span class="Italics">S</span>)-tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt.</p>
<p><span class="Bold">Figure 1: Chemical structure of cefovecin sodium</span>.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2daeaf25-f98f-49d3-943c-f604a844d93c&amp;name=convenia-01.jpg"></div>
<p>Each mL of CONVENIA reconstituted lyophile contains cefovecin sodium equivalent to 80.0 mg cefovecin, methylparaben 1.8 mg (preservative), propylparaben 0.2 mg (preservative), sodium citrate dihydrate 5.8 mg and citric acid monohydrate 0.1 mg, sodium hydroxide or hydrochloric acid as required to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>CONVENIA is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> (secondary superficial <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>) in dogs caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Staphylococcus intermedius</span> and <span class="Italics">Streptococcus canis</span> (Group G)<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>CONVENIA is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> (<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>) in cats caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pasteurella multocida</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>CONVENIA should be administered as a single subcutaneous injection of 3.6 mg/lb (8 mg/kg) body weight. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete. The decision for a second injection for any individual dog should take into consideration such factors as progress toward clinical resolution, the susceptibility of the causative organisms, and the integrity of the dog's host-defense mechanisms. Therapeutic drug concentrations after the first injection are maintained for 7 days for <span class="Italics">S. intermedius</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and for 14 days for <span class="Italics">S. canis</span> (Group G) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Maximum treatment should not exceed 2 injections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>CONVENIA should be administered as a single, one-time subcutaneous injection at a dose of 3.6 mg/lb (8 mg/kg) body weight. After an injection of CONVENIA, therapeutic concentrations are maintained for approximately 7 days for <span class="Italics">Pasteurella multocida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<p class="First"><span class="Bold">General Dosing Information</span></p>
<p>A sample of the lesion should be obtained for culture and susceptibility testing prior to beginning antimicrobial therapy. Once results become available, continue with appropriate therapy. If acceptable response to treatment is not observed, or if no improvement is seen within 3 to 4 days, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.</p>
<p>CONVENIA may persist in the body for up to 65 days. The effect of remaining concentrations of cefovecin on any subsequent antimicrobial therapies has not been determined. Fluoroquinolone and aminoglycoside antimicrobials have been reported to be compatible with cephalosporin antimicrobial agents.<span class="Sup">1,2,3</span></p>
<a name="table1"></a><table width="50%">
<caption><span>Table 1: Dose Table for CONVENIA at 8 mg/kg Body Weight</span></caption>
<col align="center" valign="middle" width="40%">
<col align="center" valign="middle" width="60%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Weight of Animal</th>
<th class="Rrule" align="center">Volume of CONVENIA<br>(3.6 mg/lb or 0.045 mL/lb)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">5 lb</td>
<td class="Rrule" align="center">0.23 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">10 lb</td>
<td class="Rrule" align="center">0.45 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">15 lb</td>
<td class="Rrule" align="center">0.67 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">20 lb</td>
<td class="Rrule" align="center">0.90 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">40 lb</td>
<td class="Rrule" align="center">1.8 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">80 lb</td>
<td class="Rrule" align="center">3.6 mL</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<p class="First"><span class="Bold">PREPARATION OF SOLUTION FOR INJECTION:</span> To deliver the appropriate dose<span class="Bold">,</span> aseptically reconstitute CONVENIA with 10 mL Sterile Water for Injection. Shake and allow vial to sit until all material is visually dissolved. The resulting solution contains cefovecin sodium equivalent to 80 mg/mL cefovecin. CONVENIA is light sensitive. The vial should be stored in the original carton and refrigerated when not in use. Use the entire contents of the vial within 56 days of reconstitution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS:</span> CONVENIA is contraindicated in dogs and cats with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to cefovecin or to β-lactam (penicillins and cephalosporins) group antimicrobials. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported with the use of this product in foreign market experience. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occurs, CONVENIA should not be administered again and appropriate therapy should be instituted. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamine, corticosteroids, and airway management, as clinically indicated. Adverse reactions may require prolonged treatment due to the prolonged systemic drug clearance (65 days).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">WARNINGS: Not for use in humans. Keep this and all drugs out of reach of children.</span> Consult a physician in case of accidental human exposure. For subcutaneous use in dogs and cats only. Antimicrobial drugs, including penicillins and cephalosporins, can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in sensitized individuals. To minimize the possibility of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, those handling such antimicrobials, including cefovecin, are advised to avoid direct contact of the product with the skin and mucous membranes.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS:</span></p>
<p>Prescribing antibacterial drugs in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant animal pathogens.</p>
<p>The safe use of CONVENIA in dogs or cats less than 4 months of age (see <span class="Bold"><a href="#as">Animal Safety</a></span>) and in breeding or lactating animals has not been determined. Safety has not been established for IM or IV administration. The long-term effects on injection sites have not been determined. CONVENIA is slowly eliminated from the body, approximately 65 days is needed to eliminate 97% of the administered dose from the body. Animals experiencing an adverse reaction may need to be monitored for this duration.</p>
<p>CONVENIA has been shown in an experimental <span class="Italics">in vitro</span> system to result in an increase in free concentrations of carprofen, furosemide, doxycycline and ketoconazole. Concurrent use of these or other drugs that have a high degree of protein-binding (e.g. NSAIDs, propofol, cardiac, anticonvulsant, and behavioral medications) may compete with cefovecin binding and cause adverse reactions.</p>
<p>Positive direct Coombs' test results and false positive reactions for glucose in the urine have been reported during treatment with some cephalosporin antimicrobials. Cephalosporin antimicrobials may also cause falsely elevated urine protein determinations. Some antimicrobials, including cephalosporins, can cause lowered albumin values due to interference with certain testing methods.</p>
<p>Occasionally, cephalosporins and NSAIDs have been associated with myelotoxicity, thereby creating a toxic <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span><span class="Sup">4</span>. Other hematological reactions seen with cephalosporins include <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and partial thromboplastin time (PTT), platelet dysfunction and transient increases in serum aminotransferases.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>A total of 320 dogs, ranging in age from 8 weeks to 19 years, were included in a field study safety analysis. Adverse reactions reported in dogs treated with CONVENIA and the active control are summarized in Table 2.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Number of Dogs<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> with Adverse Reactions Reported During the Field Study with CONVENIA</span></caption>
<col align="left" valign="middle" width="44%">
<col align="center" valign="middle" width="28%">
<col align="center" valign="middle" width="28%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Adverse Reaction</th>
<th class="Rrule" align="center">CONVENIA<br>(n=157)</th>
<th class="Rrule" align="center">Active Control<br>(n=163)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Some dogs may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>/<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Blood in Feces</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Increased <span class="product-label-link" type="condition" conceptid="197377" conceptname="Abnormal bowel sounds">Borborygmi</span></td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>Mild to moderate elevations in serum gamma glutamyl transferase or serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> were noted post-treatment in several of the CONVENIA-treated dogs. No clinical abnormalities were noted with these findings.</p>
<p>One CONVENIA-treated dog in a separate field study experienced <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> post-treatment lasting four weeks. The <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>A total of 291 cats, ranging in age from 2.4 months (one cat) to 21 years, were included in the field study safety analysis. Adverse reactions reported in cats treated with CONVENIA and the active control are summarized in Table 3.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3: Number of Cats<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> with Adverse Reactions Reported During the Field Study with CONVENIA.</span></caption>
<col align="left" valign="middle" width="44%">
<col align="center" valign="middle" width="28%">
<col align="center" valign="middle" width="28%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Adverse Reaction</th>
<th class="Rrule" align="center">CONVENIA<br>(n=147)</th>
<th class="Rrule" align="center">Active Control<br>(n=144)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Some cats may have experienced more than one adverse reaction or more than one occurrence of the same adverse reaction during the study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">14</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">26</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>/<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hyper/Acting Strange</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Inappropriate Urination</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>Four CONVENIA cases had mildly elevated post-study ALT (one case was elevated pre-study). No clinical abnormalities were noted with these findings.</p>
<p>Twenty-four CONVENIA cases had normal pre-study BUN values and elevated poststudy BUN values (37 – 39 mg/dL post-study). There were 6 CONVENIA cases with normal pre- and mildly to moderately elevated post-study creatinine values. Two of these cases also had an elevated post-study BUN. No clinical abnormalities were noted with these findings.</p>
<p>One CONVENIA-treated cat in a separate field study experienced <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> post-treatment lasting 42 days. The <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<p class="First"><span class="Underline">FOREIGN MARKET EXPERIENCE</span>: The following adverse events were reported voluntarily during post-approval use of the product in dogs and cats in foreign markets: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>/<span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">acute pulmonary edema</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4320339" conceptname="Crust">scabs</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>), <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and inappetance.</p>
<p><span class="Bold">For a copy of the Material Safety Data Sheet (MSDS) or to report a suspected adverse reaction call Zoetis Inc. at 1-888-963-8471.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY:</span></p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-10.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Cefovecin is rapidly and completely absorbed following subcutaneous administration. Non-linear kinetics is exhibited (plasma concentrations do not increase proportionally with dose). Cefovecin does not undergo hepatic metabolism and the majority of a dose is excreted unchanged in the urine. Elimination also occurs from excretion of unchanged drug in the bile. Cefovecin is a highly protein bound molecule in dog plasma (98.5%) and cat plasma (99.8%) and may compete with other highly protein bound drugs for plasma protein binding sites that could result in transient, higher free drug concentrations of either compound. Pharmacokinetic parameters following subcutaneous dosing at 8 mg/kg in the dog and cat are summarized in Table 4.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: Pharmacokinetic Parameters Reflecting Total Drug Concentrations in Plasma (mean ± standard deviation or range) Following an 8 mg/kg Intravenous or Subcutaneous Dose of Cefovecin in Dogs and Cats</span></caption>
<col align="left" valign="middle" width="66%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">PARAMETER</th>
<th class="Rrule" align="center" colspan="2">MEAN ± SD<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> or (Range)</th>
</tr>
<tr class="Last">
<th align="center">Dogs</th>
<th class="Rrule" align="center">Cats <a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>SD = standard deviation</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>= a phase effect was observed, only data for the first phase are provided (n=6); all other data provided are derived from 12 animals</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>= SC</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd>= harmonic mean</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">¶</a></dt>
<dd>= geometric mean</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">#</a></dt>
<dd>= arithmetic mean</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">Þ</a></dt>
<dd>= IV</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Terminal plasma elimination half-life, T<span class="Sub">1/2</span> (h)<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a><a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a>
</td>
<td align="center">133 ± 16</td>
<td class="Rrule" align="center">166 ± 18</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0-inf</span> (μg∙h/mL)<a href="#footnote-5" class="Sup">‡</a><a name="footnote-reference-7" href="#footnote-7" class="Sup">¶</a>
</td>
<td align="center">10400 ± 1900 <a href="#footnote-4" class="Sup">†</a>
</td>
<td class="Rrule" align="center">22700 ± 3450</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Time of maximum concentration, T<span class="Sub">max</span> (h) <a href="#footnote-5" class="Sup">‡</a><a href="#footnote-6" class="Sup">§</a>
</td>
<td align="center">6.2 (0.5-12.0)</td>
<td class="Rrule" align="center">2.0 (0.5-6.0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Maximum concentration, C<span class="Sub">max</span> (μg/mL) <a href="#footnote-5" class="Sup">‡</a><a name="footnote-reference-8" href="#footnote-8" class="Sup">#</a>
</td>
<td align="center">121 ± 51</td>
<td class="Rrule" align="center">141 ± 12</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Vd<span class="Sub">ss</span> (L/kg) <a name="footnote-reference-9" href="#footnote-9" class="Sup">Þ</a><a href="#footnote-7" class="Sup">¶</a>
</td>
<td align="center">0.122 ± 0.011</td>
<td class="Rrule" align="center">0.090 ± 0.010</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CL<span class="Sub">total</span> (mL/h/kg)<a href="#footnote-9" class="Sup">Þ</a><a href="#footnote-7" class="Sup">¶</a>
</td>
<td align="center">0.76 ± 0.13 <a href="#footnote-4" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.350 ± 0.40</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-10.2"></a><p></p>
<p class="First"><span class="Bold">Population Pharmacokinetics</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>Cefovecin plasma concentrations in the dog have been characterized by the use of population pharmacokinetic (PPK) data. Plasma cefovecin concentration data were pooled from seven laboratory pharmacokinetic studies, each involving young, normal healthy Beagle dogs. The final dataset contained 591 concentration records from 39 dogs. The simulations from the model provide the mean population estimate and the 5<span class="Sup">th</span> and 95<span class="Sup">th</span> percentile of the population estimates of total and free cefovecin concentrations over time. Figure 2 shows the predicted free plasma concentrations following administration of 8 mg/kg body weight to dogs. Based upon these predicted concentrations, 95% of the canine population will have active (free) drug concentrations &gt; the MIC<span class="Sub">90</span> of <span class="Italics">S. canis</span> (0.06 µg/mL) for approximately 14 days and free concentrations &gt; the MIC<span class="Sub">90</span> for <span class="Italics">S. intermedius</span> (0.25 μg/mL) for approximately 7 days following a single 8 mg/kg subcutaneous injection of cefovecin. (See <span class="Bold"><a href="#micro">MICROBIOLOGY</a></span>.)</p>
<p><span class="Bold">Figure 2: Population Predicted Free Concentration of Cefovecin in Plasma Following a Single Subcutaneous Injection of 8 mg/kg Body Weight in Dogs</span> (solid line is population prediction, dotted lines are the 5<span class="Sup">th</span> and 95<span class="Sup">th</span> percentiles for the population prediction).</p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2daeaf25-f98f-49d3-943c-f604a844d93c&amp;name=convenia-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>Cefovecin plasma concentrations in the cat have been characterized by the use of PPK data. Plasma cefovecin concentration data were pooled from four laboratory pharmacokinetic studies. The final dataset contained 338 concentration records from 22 cats. The simulations from the model provide the mean population estimate as well as the 5<span class="Sup">th</span> and 95<span class="Sup">th</span> percentile of the population estimates of total and free cefovecin concentrations over time. Figure 3 displays the predicted free plasma concentrations following administration of 8 mg/kg body weight to cats. Based upon these predicted concentrations, 95% of the feline population will have active (free) drug concentrations &gt; the MIC<span class="Sub">90</span> of <span class="Italics">Pasteurella multocida</span> (0.06 µg/mL) for approximately 7 days when administered a single 8 mg/kg subcutaneous injection of cefovecin. (See <span class="Bold"><a href="#micro">MICROBIOLOGY</a></span>.)</p>
<p><span class="Bold">Figure 3: Population Predicted Free Concentration of Cefovecin in Plasma Following a Single Subcutaneous Injection of 8 mg/kg Body Weight in Cats</span> (solid line is population prediction, dotted lines are the 5<span class="Sup">th</span> and 95<span class="Sup">th</span> percentiles for the population prediction).</p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2daeaf25-f98f-49d3-943c-f604a844d93c&amp;name=convenia-03.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="micro"></a><a name="section-10.3"></a><p></p>
<p class="First"><span class="Bold">MICROBIOLOGY:</span> CONVENIA is a cephalosporin antibiotic. Like other β-lactam antimicrobials, CONVENIA exerts its inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalent binding to the penicillin-binding proteins (PBPs) (i.e., transpeptidase and carboxypeptidase), which are essential for synthesis of the bacterial cell wall. For <span class="Italics">E. coli</span>, the <span class="Italics">in vitro</span> activity of CONVENIA is comparable to other cephalosporins, but due to the high-affinity protein-binding, the <span class="Italics">in vivo</span> free concentration of cefovecin does not reach the MIC<span class="Sub">90</span> for <span class="Italics">E. coli</span> (1.0 μg/mL). CONVENIA is not active against <span class="Italics">Pseudomonas</span> spp. or enterococci.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>The <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) values for cefovecin against label-claim pathogens isolated from <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> in dogs enrolled in a 2001-2003 field effectiveness study are presented in Table 5. All MICs were determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) standards.</p>
<a name="table5"></a><table width="80%">
<caption><span>Table 5. Activity of CONVENIA Against Pathogens Isolated from Dogs Treated With CONVENIA in Field Studies in the U.S. During 2001-2003.</span></caption>
<col align="left" valign="middle" width="12%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="11%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="7%">
<col align="left" valign="middle" width="7%">
<col align="left" valign="middle" width="12%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Disease</th>
<th class="Rrule" align="left">Pathogen</th>
<th class="Rrule" align="left">Microbiological Treatment Outcome</th>
<th class="Rrule" align="left">Number of Isolates</th>
<th class="Rrule" align="left">Sample Collection (Time Relative to Treatment)</th>
<th class="Rrule" align="left">MIC<span class="Sub">50</span> µg/mL</th>
<th class="Rrule" align="left">MIC<span class="Sub">90</span> µg/mL</th>
<th class="Rrule" align="left">MIC Range µg/mL</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="4"><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin infections</span></td>
<td class="Rrule" align="left" rowspan="2"><span class="Italics">Staphylococcus intermedius</span></td>
<td class="Rrule" align="left">Success</td>
<td class="Rrule" align="left">44</td>
<td class="Rrule" align="left">Pre-Treatment</td>
<td class="Rrule" align="left">0.12</td>
<td class="Rrule" align="left">0.25</td>
<td class="Rrule" align="left">≤ 0.06 - 2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Failure</td>
<td class="Rrule" align="left">4</td>
<td class="Rrule" align="left">Pre-Treatment</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">0.12 - 2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="2">
<span class="Italics">Streptococcus canis</span> (Group G)</td>
<td class="Rrule" align="left">Success</td>
<td class="Rrule" align="left">16</td>
<td class="Rrule" align="left">Pre-Treatment</td>
<td class="Rrule" align="left">≤ 0.06</td>
<td class="Rrule" align="left">≤ 0.06</td>
<td class="Rrule" align="left">≤ 0.06</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Failure</td>
<td class="Rrule" align="left">2</td>
<td class="Rrule" align="left">Pre-Treatment</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">≤ 0.06</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.3.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>The MIC values for cefovecin against <span class="Italics">Pasteurella multocida</span> isolated from <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> (<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>) in cats enrolled in a 2001-2003 field effectiveness study are presented in Table 6. All MICs were determined in accordance with the CLSI standards.</p>
<a name="table6"></a><table width="80%">
<caption><span>Table 6. Activity of CONVENIA Against Pathogens Isolated from Cats Treated With CONVENIA in Field Studies in the U.S. During 2001-2003.</span></caption>
<col align="left" valign="middle" width="12%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="11%">
<col align="left" valign="middle" width="17%">
<col align="left" valign="middle" width="7%">
<col align="left" valign="middle" width="7%">
<col align="left" valign="middle" width="12%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Disease</th>
<th class="Rrule" align="left">Pathogen</th>
<th class="Rrule" align="left">Microbiological Treatment Outcome</th>
<th class="Rrule" align="left">Number of Isolates</th>
<th class="Rrule" align="left">Sample Collection (Time Relative to Treatment)</th>
<th class="Rrule" align="left">MIC<span class="Sub">50</span> µg/mL</th>
<th class="Rrule" align="left">MIC<span class="Sub">90</span> µg/mL</th>
<th class="Rrule" align="left">MIC Range µg/mL</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="2"><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin infections</span></td>
<td class="Rrule" align="left" rowspan="2"><span class="Italics">Pasteurella multocida</span></td>
<td class="Rrule" align="left">Success</td>
<td class="Rrule" align="left">57</td>
<td class="Rrule" align="left">Pre-Treatment</td>
<td class="Rrule" align="left">≤ 0.06</td>
<td class="Rrule" align="left">≤ 0.06</td>
<td class="Rrule" align="left">≤ 0.06 -0.12</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Failure</td>
<td class="Rrule" align="left">1</td>
<td class="Rrule" align="left">Pre-Treatment</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">≤ 0.06</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">EFFECTIVENESS:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>In a double-masked, 1:1 randomized canine field study conducted in the United States, the effectiveness of CONVENIA was compared to a cephalosporin active control. In this study, 320 dogs with superficial secondary <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, or infected <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> were treated with either a single injection of CONVENIA (n = 157) at 3.6 mg/lb (8 mg/kg) body weight or with an oral active control antibiotic (n = 163), administered twice daily for 14 days. In this study, dogs could receive a second course of therapy 14 days after the initial treatment. Of the 320 enrolled dogs, 22 of 157 dogs received two treatments of CONVENIA and 35 of 163 dogs received two courses of treatment with the active control. In the study, 118 of the 157 enrolled cases were evaluable for effectiveness for CONVENIA, and 117 of the 163 enrolled cases were evaluable for effectiveness of the active control antibiotic. CONVENIA was non-inferior to the active control. Table 7 summarizes the clinical success rates obtained 28 days after the initiation of the final course of therapy.</p>
<a name="table7"></a><table width="75%">
<caption><span>Table 7: Clinical Success Rates by Treatment Group 28 Days after the Initiation of the Final Course of Therapy.</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></th>
<th class="Rrule" align="center" colspan="2">Dogs</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">CONVENIA<br>(n=118)</th>
<th class="Rrule" align="center">Active Control<br>(n=117)</th>
</tr>
</thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Skin (secondary superficial <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>, and infected <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>)</td>
<td class="Rrule" align="center">109 (92.4%)</td>
<td class="Rrule" align="center">108 (92.3%)</td>
</tr></tbody>
</table>
<p>CONVENIA was administered concomitantly with other commonly used veterinary products such as heartworm preventatives, flea control products, sedatives/tranquilizers, anesthetic agents, routine immunizations, antihistamines, thyroid hormone supplementation, and non-steroidal anti-inflammatory drugs during the field study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>In a double-masked, 1:1 randomized cat field study conducted in the United States, the effectiveness of CONVENIA was compared to an active control. In this study, 291 cats with infected <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> or <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> were treated with either a single injection of CONVENIA (n = 147) at 3.6 mg/lb (8 mg/kg) body weight or with an oral active control antibiotic (n = 144), administered once daily for 14 days. CONVENIA was non-inferior to the active control. The clinical success rates were obtained 28 days after the initiation of therapy and are presented in Table 8.</p>
<a name="table8"></a><table width="75%">
<caption><span>Table 8: Clinical Success Rates by Treatment Group 28 Days after the Initiation of Therapy.</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Type of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></th>
<th class="Rrule" align="center" colspan="2">Cats</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">CONVENIA<br>(n=89)</th>
<th class="Rrule" align="center">Active Control<br>(n=88)</th>
</tr>
</thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Skin (<span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>)</td>
<td class="Rrule" align="center">86 (96.6%)</td>
<td class="Rrule" align="center">80 (90.9%)</td>
</tr></tbody>
</table>
<p>CONVENIA was used concomitantly with other commonly used veterinary products such as heartworm preventatives, flea control products, sedatives/tranquilizers, anesthetic agents, and vaccines during the field study.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="as"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">ANIMAL SAFETY:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Dogs</span></p>
<p>CONVENIA administered to healthy four month old dogs at doses of 12 mg/kg (1.5 ×), 36 mg/kg (4.5 ×), and 60 mg/kg (7.5 ×) every seven days by dorsoscapular subcutaneous injections was well-tolerated for a total of 5 doses. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were seen in all treatment groups, with the incidence of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and the incidence and duration of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> increasing in a dose-related manner. <span class="product-label-link" type="condition" conceptid="4317272" conceptname="Injection site irritation">Injection site irritation</span> and transient <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> occurred with increasing frequency in a dose-related manner and with repeat injections. Two <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> included a <span class="product-label-link" type="condition" conceptid="4209136" conceptname="Seroma">seroma</span> over the shoulder and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> lasting &gt; 30 days. Dogs dosed at 36 mg/kg had a significant (p = 0.0088) increase in BUN (all means remained within the normal range) compared to the controls. One dog dosed at 60 mg/kg exhibited a glomerulopathy on histopathology, and one dog in this same group had minimal <span class="product-label-link" type="condition" conceptid="4240725" conceptname="Peliosis hepatis">peliosis hepatis</span>.</p>
<p>At an exaggerated dose of 180 mg/kg (22.5×) in dogs, CONVENIA caused some <span class="product-label-link" type="condition" conceptid="4317272" conceptname="Injection site irritation">injection site irritation</span>, vocalization and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> resolved within 8-24 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<p class="First"><span class="Bold">Cats</span></p>
<p>CONVENIA administered to healthy four month old cats at doses of 12 mg/kg (1.5 ×), 36 mg/kg (4.5 ×), and 60 mg/kg (7.5 ×) every seven days by dorsoscapular subcutaneous injections was well tolerated for a total of 5 doses. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were observed in cats, with the incidence of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and the incidence and duration of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> increasing in a dose-related manner. The mean albumin values for all the CONVENIA-treated cats were significantly lower (p ≤ 0.05) than the control values (all means remained within the normal range) for all time periods. The mean alkaline phosphatase values in the 60 mg/kg group were significantly higher (p ≤ 0.0291) than the control values for all time periods. Injection-site irritation and transient <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> occurred with increasing frequency in a dose-related manner and with repeat injections. One cat in the 12 mg/kg group had a mild renal tubular and interstitial <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, and one cat in the 12 mg/kg group had mild glomerulosclerosis on histopathology.</p>
<p>At an exaggerated dose of 180 mg/kg (22.5×), CONVENIA was associated with <span class="product-label-link" type="condition" conceptid="4317272" conceptname="Injection site irritation">injection site irritation</span>, vocalization and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> resolved within 8-24 hours. On Day 10, cats had lower mean white blood cell counts compared to the controls. One cat had a small amount of <span class="product-label-link" type="condition" conceptid="4172937" conceptname="Bilirubinuria">bilirubinuria</span> on Day 10.</p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">STORAGE INFORMATION:</span></p>
<p>Store the powder and the reconstituted product in the original carton, refrigerated at 2° to 8° C (36° to 46° F). <span class="Bold">Use the entire contents of the vial within 56 days of reconstitution</span>. PROTECT FROM LIGHT. After each use it is important to return the unused portion back to the refrigerator in the original carton. As with other cephalosporins, the color of the solution may vary from clear to amber at reconstitution and may darken over time. If stored as recommended, solution color does not adversely affect potency.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">HOW SUPPLIED:</span></p>
<p>CONVENIA is available as a 10 mL multi-use vial containing 800 milligrams of cefovecin as a lyophilized cake.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">REFERENCES:</span></p>
<p><span class="Sup">1</span>Pillai SK, Moellering RC, and Eliopoulos GM. 2005. Antimicrobial combinations, pp 365-440. In V. Lorian (ed.) <span class="Underline">Antibiotics in Laboratory Medicine</span>, 5<span class="Sup">th</span> ed., Lippincott, Williams, and Wilkins, Philadelphia, PA.</p>
<p><span class="Sup">2</span>Fish DN, Choi MK, and Jung R: Synergic activity of cephalosporins plus fluoroquinolones against <span class="Italics">Pseudomonas aeruginosa</span> with resistance to one or both drugs. <span class="Italics">Journal of Antimicrobial Chemotherapy</span> (2002) 50, 1045–1049.</p>
<p><span class="Sup">3</span>Mayer I and Nagy E: Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of <span class="Italics">Pseudomonas</span> spp. <span class="Italics">Journal of Antimicrobial Chemotherapy</span> (1999) 43, 651–657.</p>
<p><span class="Sup">4</span>Birchard SJ and Sherding RG. <span class="Underline">Saunders Manual of Small Animal Practice</span>, 2<span class="Sup">nd</span> edition. W.B. Saunders Co. 2000: p. 166.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">NADA# 141-285, Approved by FDA</span></p>
<p>Distributed by:<br>Zoetis Inc.<br>Kalamazoo, MI 49007</p>
<p>Revised: January 2013<br>PAA035845</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</h1>
<p class="First"><span class="Bold">convenia<span class="Sup">®</span></span><br>cefovecin sodium</p>
<p><span class="Bold">Antimicrobial For Subcutaneous<br>Injection in Dogs and Cats Only</span></p>
<p><span class="Bold">Caution:</span> Federal (USA) law restricts<br>this drug to use by or on the order<br>of a licensed veterinarian.</p>
<p>80 mg/mL</p>
<p><span class="Bold">Net Contents: 10 mL</span> (when reconstituted)</p>
<p>NADA # 141-285, Approved by FDA</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2daeaf25-f98f-49d3-943c-f604a844d93c&amp;name=convenia-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CONVENIA 		
					</strong><br><span class="contentTableReg">cefovecin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-1520</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cefovecin sodium</strong> (cefovecin) </td>
<td class="formItem">cefovecin</td>
<td class="formItem">80 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">1.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylparaben</strong></td>
<td class="formItem">0.2 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem">5.8 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>citric acid monohydrate</strong></td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-1520-1</td>
<td class="formItem">10 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141285</td>
<td class="formItem">04/25/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Zoetis Inc.
							(828851555)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Zoetis LLC</td>
<td class="formItem"></td>
<td class="formItem">039055157</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Zoetis P &amp; U LLC</td>
<td class="formItem"></td>
<td class="formItem">078822438</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Global Supply</td>
<td class="formItem"></td>
<td class="formItem">200006526</td>
<td class="formItem">API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8f25cae2-988d-4d4e-9520-7644a96eb950</div>
<div>Set id: 2daeaf25-f98f-49d3-943c-f604a844d93c</div>
<div>Version: 2</div>
<div>Effective Time: 20141107</div>
</div>
</div> <div class="DistributorName">Zoetis Inc.</div></p>
</body></html>
